Cosmo Pharmaceuticals’ shares rise after Phase 3 win in male pattern hair lossnews2025-12-03T12:11:32+00:00December 3rd, 2025|Endpoints News|
Helicore stops work on clinical GIP antagonist after Phase 1 resultsnews2025-12-02T13:46:05+00:00December 2nd, 2025|Endpoints News|
Vandria plots Series B raise to advance Alzheimer’s drug into Phase 2news2025-12-02T08:00:53+00:00December 2nd, 2025|Endpoints News|
Janux’s prostate cancer immunotherapy’s response rate drops, according to new early-stage datanews2025-12-01T21:10:17+00:00December 1st, 2025|Endpoints News|
Belite Bio aims for first approval of Stargardt disease treatment with Phase 3 successnews2025-12-01T18:22:00+00:00December 1st, 2025|Endpoints News|
Gene writing startup Tessera strikes $150M partnership with Regeneronnews2025-12-01T12:00:18+00:00December 1st, 2025|Endpoints News|
Generate:Biomedicines to start Phase 3 studies for TSLP antibodynews2025-12-01T11:00:16+00:00December 1st, 2025|Endpoints News|
China’s Zhongmou seeks to create a ‘one-size-fits-all’ rival to Luxturnanews2025-11-26T13:31:07+00:00November 26th, 2025|Endpoints News|
Kallyope scraps one of two mid-stage migraine drugsnews2025-11-26T10:37:29+00:00November 26th, 2025|Endpoints News|
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trialnews2025-11-25T14:31:02+00:00November 25th, 2025|Endpoints News|
